Eli Lilly and Co.

Research reforms will force Lilly, others to test how drugs stack upRestricted Content

June 12, 2010
J.K. Wall
The federal government is currently doling out $1.1 billion in stimulus funds to pay for research that compares multiple medical treatments against one another to determine which is most effective. Drug companies like Eli Lilly and Co. are wary that comparative-effectiveness research could threaten their sales.
More

Lilly taps O'Connor as state lobbyist

June 9, 2010
J.K. Wall
O’Connor, chief deputy mayor under former Indianapolis Mayor Bart Peterson, started Monday as Lilly's director of state government affairs—working again under Peterson.
More

Erbitux fails to stop colon cancer before it spreads

June 6, 2010
Bloomberg News
Eli Lilly and Co. and Merck KGaA drug failed to slow tumors in a study designed to expand the medicine's use to patients whose disease is in an earlier stage.
More

Genetic testing could spur Erbitux drug sales

June 1, 2010
Bloomberg News
The drugmakers are counting on screening for the so-called K-ras gene to spur use of Erbitux in metastatic colorectal cancer.
More

Lilly grows Alimta's sales by shrinking marketRestricted Content

May 29, 2010
J.K. Wall
In 2008, Eli Lilly and Co. asked drug regulators to change the label on Alimta so Lilly could no longer promote it as a treatment for all patients suffering from non-small-cell lung cancer, but for only about 70 percent of the patients. Since then, sales of the drug have accelerated, growing a whopping 48 percent last year.
More

Indianapolis startup attacks Alzheimer's diseaseRestricted Content

May 29, 2010
Norm Heikens
AgeneBio Inc. this month landed a $300,000 investment from the Indiana Seed Fund to fund operations, bolster its intellectual property, and begin learning how to make a drug into a once-a-day pill.
More

Eli Lilly invests in $250M Australian venture fund

May 20, 2010
 IBJ Staff and Bloomberg News
The unnamed venture fund will be based in Brisbane, and will focus on biotechnology investments in Australia and southeastern Asia.
More

Drug-spending increase highest in four years

May 20, 2010
Bloomberg News
The price increase was fueled by the debate over the health-care overhaul in Washington, D.C., Medco Health Solutions Inc. CEO David Snow said.
More

Lilly, others cut U.S. tax bills through transfer pricing

May 14, 2010
Bloomberg News
U.S. companies, including Eli Lilly, amassed at least $1 trillion in foreign profits not taxed in the U.S. as of the end of last year. That cumulative total increased 70 percent over three years.
More

Lilly still waiting on once-weekly Byetta

May 12, 2010
J.K. Wall
The U.S. Food and Drug Administration last week pushed its self-declared deadline for rendering an approval decision on the drug Bydureon to Oct. 22. The previous deadline was in March.
More

Lilly hopes Elanco unit becomes a cash cow

May 8, 2010
J.K. Wall
Elanco Animal Health chief Jeff Simmons predicts that consumers will opt for food made cheaper by using Elanco's productivity-enhancing drugs over pricier organic and locally grown products. But, as a hedge, he has Elanco developing products to help organic farmers, too.
More

Latest Lilly job cuts target marketing employees

May 7, 2010
J.K. Wall
Indianapolis-based drugmaker Eli Lilly and Co. is on course to cut 5,500 jobs by the end of 2011 in a bid to eliminate $1 billion in annual expenses.
More

Lilly sues to block copy of Evista osteoporosis drug

May 5, 2010
Bloomberg News
Watson Pharmaceuticals filed for FDA approval to sell a low-cost version of Eli Lilly and Co.'s osteoporosis medicine. Indianapolis-based Lilly is seeking a court order that would block approval until three of its patents expire in 2017.
More

Drug prices rise ahead of rebates

April 21, 2010
J.K. Wall
Drug prices rose faster last year than they have in a decade—just in time for big rebates the drug industry promised as part of the health reform law.
More

Shareholders fail to remove Lilly's anti-takeover provision

April 19, 2010
J.K. Wall
The proposal to remove an 80-percent approval threshold for takeover bids against the wishes of Lilly’s board received approval from shareholders holding 74 percent of Lilly’s shares.
More

Shares fall after Lilly earnings report

April 19, 2010
J.K. Wall
Lilly shareholders are set to gather Monday in Indianapolis to hear an update on the company’s performance, including how it will keep paying its generous dividend during the lean years after Zyprexa’s patent expiration.
More

Lilly to pay $400M to repurchase Cymbalta rights

April 19, 2010
Bloomberg News
Eli Lilly and Co. will repurchase rights to develop and market antidepressant Cymbalta outside the U.S. and Japan from European partner Boehringer Ingelheim for an initial payment of $400 million.
More

Health reform dings Lilly's earnings

April 19, 2010
J.K. Wall
The Indianapolis-based drugmaker also lowered its forecast for full-year profits because the new health care law grants bigger rebates on prescription drugs to federal health insurance programs.
More

Can Lilly afford to maintain its dividend?Restricted Content

April 17, 2010
J.K. Wall
As shareholders gather April 19 for Eli Lilly and Co.'s annual meeting, more of them than ever will come with an unusual question: Will Lilly be able to keep paying its dividend?
More

Lilly sets date for move from Faris campus downtown

April 12, 2010
Work force reductions, new business structure make leased office space unnecessary. Moves will begin in late June.
More

Lilly diabetes drug may have cancer risk, FDA says

April 9, 2010
 IBJ Staff and Bloomberg News
Once-weekly form of Byetta is awaiting the FDA's OK. Analyst predict the new version of the drug, if approved, could rack up sales of $2 billion annually.
More

Louisiana gets $20M in Lilly drug settlement

April 7, 2010
Associated Press
Louisiana was one of 13 states that filed individual suits in state courts over allegations that Lilly pushed Zyprexa for uses that had not been approved by federal regulators.
More

Lilly wins court ban on generic copy of Gemzar

April 1, 2010
Bloomberg News, Associated Press
Eli Lilly and Co. won a U.S. court ruling Wednesday that bars Teva Pharmaceutical Industries Ltd. from selling a generic version of the cancer drug Gemzar until November.
More

Lilly drug wins U.K. backing as cancer therapy

April 1, 2010
Bloomberg News
Eli Lilly and Co.'s Alimta has received the preliminary backing of a United Kingdom agency as a maintenance treatment for patients with the most common form of lung cancer.
More

Lilly to let 115 workers go in new outsourcing deal

March 26, 2010
J.K. Wall
Deal with unit of Massachusetts-based Thermo Fisher Scientific would keep many of the employees working in same location.
More
Page  << 11 12 13 14 15 16 17 18 19 20 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. With Pence running the ship good luck with a new government building on the site. He does everything on the cheap except unnecessary roads line a new beltway( like we need that). Things like state of the art office buildings and light rail will never be seen as an asset to these types. They don't get that these are the things that help a city prosper.

  2. Does the $100,000,000,000 include salaries for members of Congress?

  3. "But that doesn't change how the piece plays to most of the people who will see it." If it stands out so little during the day as you seem to suggest maybe most of the people who actually see it will be those present when it is dark enough to experience its full effects.

  4. That's the mentality of most retail marketers. In this case Leo was asked to build the brand. HHG then had a bad sales quarter and rather than stay the course, now want to go back to the schlock that Zimmerman provides (at a considerable cut in price.) And while HHG salesmen are, by far, the pushiest salesmen I have ever experienced, I believe they are NOT paid on commission. But that doesn't mean they aren't trained to be aggressive.

  5. The reason HHG's sales team hits you from the moment you walk through the door is the same reason car salesmen do the same thing: Commission. HHG's folks are paid by commission they and need to hit sales targets or get cut, while BB does not. The sales figures are aggressive, so turnover rate is high. Electronics are the largest commission earners along with non-needed warranties, service plans etc, known in the industry as 'cheese'. The wholesale base price is listed on the cryptic price tag in the string of numbers near the bar code. Know how to decipher it and you get things at cost, with little to no commission to the sales persons. Whether or not this is fair, is more of a moral question than a financial one.

ADVERTISEMENT